2017-03-15,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
2017-02-23,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2017-02-06,Aclaris Therapeutics is Now Oversold (ACRS)
2017-02-06,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2017-02-06,Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
2017-02-06,New Skin Lesion Drug Only Scratches Market's Surface, Says Aclaris CEO
2017-01-26,Aclaris Therapeutics Announces Appointment Of Andrew Powell To Board Of Directors
2017-01-03,Aclaris To Present At 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Commit To Buy Aclaris Therapeutics At $22.50, Earn 12.2% Annualized Using Options
2016-12-07,Aclaris Therapeutics Initiates Phase 1 Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis
2016-11-22,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2016-11-17,Aclaris Announces Pricing Of Public Offering Of Common Stock
2016-11-16,Aclaris Announces Proposed Public Offering Of Common Stock
2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
2016-11-03,Aclaris Therapeutics Reports Third Quarter 2016 Financial Results
2016-10-31,Aclaris Therapeutics Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis
2016-10-28,Aclaris Therapeutics Honored As One Of The Best Places To Work In Pennsylvania
2016-10-27,Aclaris Therapeutics Becomes Oversold
2016-10-25,Aclaris Therapeutics To Announce Third Quarter 2016 Financial Results On November 3, 2016
2016-10-19,New Observational Study Demonstrates Patient Impact Of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
2016-09-06,Aclaris Therapeutics To Present At The Morgan Stanley 2016 Healthcare Conference
2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
2016-08-11,Aclaris Therapeutics Reports Second Quarter 2016 Financial Results
2016-08-04,Aclaris Announces Appointment Of Bill Humphries To Board Of Directors
2016-08-02,Aclaris Therapeutics To Announce Second Quarter 2016 Financial Results On August 11, 2016
2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
2016-07-13,Short Interest Surges 58% For ACRS
2016-07-05,Aclaris Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-05-31,Aclaris Therapeutics To Present At Upcoming Investor Conferences In June
2016-05-27,Aclaris Therapeutics Announces $20.0 Million Private Placement
2016-05-11,Aclaris Therapeutics Reports First Quarter 2016 Financial Results
2016-05-05,Aclaris Therapeutics, Inc. Appoints Kevin Scott As Vice President Of Sales
2016-05-02,Aclaris Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference
2016-04-26,Aclaris Therapeutics To Announce First Quarter 2016 Financial Results On May 11, 2016
2016-03-28,Aclaris Therapeutics Acquires Worldwide Rights To Compounds And Key Intellectual Property For Potential Treatment For Hair Loss
2016-03-23,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-03-17,Aclaris Therapeutics Becomes Oversold (ACRS)
2016-03-17,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On March 23, 2016
2016-02-17,Aclaris Therapeutics Enters Oversold Territory
2016-02-05,Aclaris Therapeutics To Present At The 2016 Leerink Partners Annual Global Healthcare Conference
2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
2015-12-22,Aclaris Therapeutics, Inc. Added To Russell 2000® Index
2015-12-16,Aclaris Therapeutics, Inc. Appoints Brett Fair As Senior Vice President Of Commercial Operations
2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
2015-11-18,Aclaris Therapeutics Reports Third Quarter 2015 Financial Results
2015-11-04,5 Stocks With Big Insider Buying -- Should You Love Them Too?
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-13,Aclaris Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
,
,
,
,
2017-03-15,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
2017-02-23,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
2017-02-06,Aclaris Therapeutics is Now Oversold (ACRS)
2017-02-06,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2017-02-06,Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
2017-02-06,New Skin Lesion Drug Only Scratches Market's Surface, Says Aclaris CEO
2017-01-26,Aclaris Therapeutics Announces Appointment Of Andrew Powell To Board Of Directors
2017-01-03,Aclaris To Present At 35th Annual J.P. Morgan Healthcare Conference
2016-12-28,Commit To Buy Aclaris Therapeutics At $22.50, Earn 12.2% Annualized Using Options
2016-12-07,Aclaris Therapeutics Initiates Phase 1 Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis
2016-11-22,Aclaris Therapeutics To Attend Upcoming Investor Conferences
2016-11-17,Aclaris Announces Pricing Of Public Offering Of Common Stock
2016-11-16,Aclaris Announces Proposed Public Offering Of Common Stock
2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
2016-11-03,Aclaris Therapeutics Reports Third Quarter 2016 Financial Results
2016-10-31,Aclaris Therapeutics Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis
2016-10-28,Aclaris Therapeutics Honored As One Of The Best Places To Work In Pennsylvania
2016-10-27,Aclaris Therapeutics Becomes Oversold
2016-10-25,Aclaris Therapeutics To Announce Third Quarter 2016 Financial Results On November 3, 2016
2016-10-19,New Observational Study Demonstrates Patient Impact Of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
2016-09-06,Aclaris Therapeutics To Present At The Morgan Stanley 2016 Healthcare Conference
2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
2016-08-11,Aclaris Therapeutics Reports Second Quarter 2016 Financial Results
2016-08-04,Aclaris Announces Appointment Of Bill Humphries To Board Of Directors
2016-08-02,Aclaris Therapeutics To Announce Second Quarter 2016 Financial Results On August 11, 2016
2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
2016-07-13,Short Interest Surges 58% For ACRS
2016-07-05,Aclaris Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-05-31,Aclaris Therapeutics To Present At Upcoming Investor Conferences In June
2016-05-27,Aclaris Therapeutics Announces $20.0 Million Private Placement
2016-05-11,Aclaris Therapeutics Reports First Quarter 2016 Financial Results
2016-05-05,Aclaris Therapeutics, Inc. Appoints Kevin Scott As Vice President Of Sales
2016-05-02,Aclaris Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Healthcare Conference
2016-04-26,Aclaris Therapeutics To Announce First Quarter 2016 Financial Results On May 11, 2016
2016-03-28,Aclaris Therapeutics Acquires Worldwide Rights To Compounds And Key Intellectual Property For Potential Treatment For Hair Loss
2016-03-23,Aclaris Therapeutics Reports Fourth Quarter And Full Year 2015 Operating And Financial Results
2016-03-17,Aclaris Therapeutics Becomes Oversold (ACRS)
2016-03-17,Aclaris Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On March 23, 2016
2016-02-17,Aclaris Therapeutics Enters Oversold Territory
2016-02-05,Aclaris Therapeutics To Present At The 2016 Leerink Partners Annual Global Healthcare Conference
2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
2015-12-22,Aclaris Therapeutics, Inc. Added To Russell 2000® Index
2015-12-16,Aclaris Therapeutics, Inc. Appoints Brett Fair As Senior Vice President Of Commercial Operations
2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
2015-11-18,Aclaris Therapeutics Reports Third Quarter 2015 Financial Results
2015-11-04,5 Stocks With Big Insider Buying -- Should You Love Them Too?
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-13,Aclaris Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-10-07,Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
,
,
,
,
